These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 14642631)

  • 1. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.
    Villeneuve JP; Durantel D; Durantel S; Westland C; Xiong S; Brosgart CL; Gibbs CS; Parvaz P; Werle B; Trépo C; Zoulim F
    J Hepatol; 2003 Dec; 39(6):1085-9. PubMed ID: 14642631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern.
    Inoue J; Ueno Y; Wakui Y; Niitsuma H; Fukushima K; Yamagiwa Y; Shiina M; Kondo Y; Kakazu E; Tamai K; Obara N; Iwasaki T; Shimosegawa T
    J Viral Hepat; 2011 Mar; 18(3):206-15. PubMed ID: 20367795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selection of a multiple drug-resistant hepatitis B virus strain in a liver-transplanted patient.
    Villet S; Pichoud C; Villeneuve JP; Trépo C; Zoulim F
    Gastroenterology; 2006 Oct; 131(4):1253-61. PubMed ID: 17030194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
    Brunelle MN; Jacquard AC; Pichoud C; Durantel D; Carrouée-Durantel S; Villeneuve JP; Trépo C; Zoulim F
    Hepatology; 2005 Jun; 41(6):1391-8. PubMed ID: 15915463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Core promoter mutant HBV non-responding to adefovir after viral breakthrough on lamivudine: rapid virologic response to tenofovir plus lamivudine in a cirrhotic patient.
    Katsounas A; Jochum C; Canbay A; Schlaak J; Gerlich WH; Gerken G
    Eur J Med Res; 2008 Oct; 13(10):472-5. PubMed ID: 19008175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Aizawa M; Tsubota A; Fujise K; Tatsuzawa K; Kono M; Hoshina S; Tajiri H
    J Med Virol; 2011 Jun; 83(6):953-61. PubMed ID: 21503906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.
    Heo NY; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
    J Hepatol; 2010 Sep; 53(3):449-54. PubMed ID: 20646776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The rtA181S mutation of hepatitis B virus primarily confers resistance to adefovir dipivoxil.
    Liu Y; Li X; Xin S; Xu Z; Chen R; Yang J; Liu L; Wong VW; Yang D; Chan HL; Xu D
    J Viral Hepat; 2015 Mar; 22(3):328-34. PubMed ID: 25132017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance.
    Chen CH; Lee CM; Tung WC; Wang JH; Hung CH; Hu TH; Wang JC; Lu SN; Changchien CS
    J Hepatol; 2010 Apr; 52(4):478-85. PubMed ID: 20185198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection].
    Moon JH; Cho M; Yoon KT; Bae JH; Heo J; Kim GH; Kang DH; Song GA
    Korean J Hepatol; 2008 Dec; 14(4):503-12. PubMed ID: 19119245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of viral load and changes of polymerase and precore/core promoter sequences in lamivudine-resistant hepatitis B virus during adefovir therapy.
    Chang UI; Lee YC; Wie SH; Jang JW; Bae SH; Choi JY; Yang JM; Yoon SK; Sun HS
    J Med Virol; 2007 Jul; 79(7):902-10. PubMed ID: 17516533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ; Park JH; Park DI; Cho YK; Sohn CI; Jeon WK; Kim BI
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver transplantation for chronic hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine.
    Lo CM; Liu CL; Lau GK; Chan SC; Ng IO; Fan ST
    Liver Transpl; 2005 Jul; 11(7):807-813. PubMed ID: 15973721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
    Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
    Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rescue therapy for lamivudine-resistant chronic hepatitis B: adefovir monotherapy, adefovir plus lamivudine or entecavir combination therapy.
    Ha M; Zhang G; Diao S; Lin M; Wu J; Sun L; She H; Shen L; Huang C; Shen W; Huang Z
    Intern Med; 2012; 51(12):1509-15. PubMed ID: 22728482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
    Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
    J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: clonal evolution during lamivudine plus adefovir therapy.
    Kim SS; Cho SW; Kim SO; Hong SP; Cheong JY
    J Med Virol; 2013 Jan; 85(1):55-64. PubMed ID: 23096938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The rate of hepatitis B virus resistance to adefovir dipivoxil (ADV) and the evolution of hepatitis B virus in lamivudine-resistant chronic hepatitis B patients with ADV monotherapy].
    Qin YL; Zhang JM; Huang YX; Mao RC; Yin YK; Zhang WQ; Zhang QB; Wu XH; Weng XH
    Zhonghua Gan Zang Bing Za Zhi; 2007 Jan; 15(1):4-7. PubMed ID: 17244449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY; Chuang WL; Hsieh MY; Lee LP; Huang JF; Hou NJ; Lin ZY; Chen SC; Hsieh MY; Wang LY; Tsai JF; Chang WY; Yu ML
    Antiviral Res; 2007 Aug; 75(2):146-51. PubMed ID: 17400303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.